Indeed, platelets coupled with anti-PD-L1 release the therapeutic antibody upon activation, presumably via dissociation or release of PMVs, thereby facilitating anti-PD-L1 transport and ensuring effective targeting of remaining cancer cells in a murine model of tumor ablation (Han et al., 2019). Here, CD274 is linked to neoplasm.